about
Genetically stable picornavirus expression vectors with recombinant internal ribosomal entry sitesApplication of chimeric feline foamy virus-based retroviral vectors for the induction of antiviral immunity in cats.Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine.Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yUse of viral vectors for the development of vaccines.Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States.Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein geneHIV/AIDS vaccines: a need for new concepts?Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors.Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.Applications and challenges of multivalent recombinant vaccines.Kinetics and characteristics of replication-competent revertants derived from self-inactivating foamy virus vectors.
P2860
Q34361592-D83DC19F-3B20-49B5-BBA7-06EC8D3D9490Q35104790-C797E8C1-5DA9-4AA1-AD19-A021E2DA0ED1Q35193454-B4F4B664-6B88-4975-9027-B5101EF3B63AQ36010016-1C8B42F7-46D4-49BA-A1DE-8B560A0A49A5Q36294739-9E83BBEB-0D34-4BBA-B8DB-591C72956E2CQ36474235-01241BD0-DAA3-4EDB-BD7A-0C3BA3EAD593Q36498186-7622685D-6D8D-4E95-BCF4-6999A151C35AQ36541222-20E51969-C910-48EA-9C17-3FECF52A3E04Q36780156-01A7F58F-A666-4CCF-B3A7-627AD0E5E4B4Q37015368-8FC358CB-32D9-49D7-9F3C-0D1C3A7AD2A0Q37068893-DA46DD61-8B37-4C7D-A12A-0B9E2B9F84F7Q37344236-CFE1FB5E-8513-4BE4-8EF8-CF4291CE2830Q37348513-B4B8E5F4-209C-4C86-A936-887D4898459EQ37478331-C33B2A64-E38B-4EFD-8129-ADAF8CE776B9Q38068270-4FE5500B-E227-4AF1-B114-F10ED3DD3ECFQ45674657-E5ED11CC-BE27-4BC5-819E-02607F7EA72A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Viral vectors as potential HIV-1 vaccines.
@ast
Viral vectors as potential HIV-1 vaccines.
@en
Viral vectors as potential HIV-1 vaccines.
@nl
type
label
Viral vectors as potential HIV-1 vaccines.
@ast
Viral vectors as potential HIV-1 vaccines.
@en
Viral vectors as potential HIV-1 vaccines.
@nl
prefLabel
Viral vectors as potential HIV-1 vaccines.
@ast
Viral vectors as potential HIV-1 vaccines.
@en
Viral vectors as potential HIV-1 vaccines.
@nl
P1476
Viral vectors as potential HIV-1 vaccines.
@en
P2093
Schnell MJ
P304
P356
10.1111/J.1574-6968.2001.TB10703.X
P577
2001-06-01T00:00:00Z